IGM Biosciences Inc Cash Flow Conversion Efficiency
IGM Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, IGM Biosciences Inc (IGMS) has a cash flow conversion efficiency ratio of -0.503x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-50.79 Million) by net assets ($100.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of IGM Biosciences Inc (2017–2024)
Cash flow conversion efficiency of IGM Biosciences Inc from 2017 to 2024. This chart illustrates how IGM Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View IGM Biosciences Inc share price for real-time trading data and today's change.
IGM Biosciences Inc Cash Flow Conversion Ratio Explained
IGM Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
IGM Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IGM Biosciences Inc ranked by their cash flow conversion efficiency. Also see IGMS market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kuangli Photoelectric Technology Co Ltd
TW:6431
|
-0.117x |
|
Somnomed Ltd
AU:SOM
|
0.083x |
|
Metair
JSE:MTA
|
-0.172x |
|
SAMYOUNG M-Tek Co. Ltd
KQ:054540
|
0.013x |
|
Chosun Welding
KO:120030
|
0.055x |
|
Forum Markets, Incorporated
NASDAQ:FRMM
|
-0.097x |
|
Experience Co Ltd
AU:EXP
|
0.044x |
|
51 CREDIT CARD DL-00001
F:2JY
|
N/A |
Annual Cash Flow Conversion Efficiency for IGM Biosciences Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of IGM Biosciences Inc from 2017 to 2024. Review how much free cash does IGM Biosciences Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $48.17 Million | $-153.00 Million | -3.176x | -235.78% |
| 2023-12-31 | $203.23 Million | $-192.23 Million | -0.946x | -4542.25% |
| 2022-12-31 | $287.26 Million | $-5.85 Million | -0.020x | +95.99% |
| 2021-12-31 | $244.91 Million | $-124.34 Million | -0.508x | -188.02% |
| 2020-12-31 | $381.81 Million | $-67.30 Million | -0.176x | +6.14% |
| 2019-12-31 | $240.23 Million | $-45.12 Million | -0.188x | -161.68% |
| 2018-12-31 | $-65.83 Million | $-20.04 Million | 0.304x | +19.08% |
| 2017-12-31 | $-40.50 Million | $-10.36 Million | 0.256x | -- |
About IGM Biosciences Inc
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, In… Read more